Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases
- PMID: 24468877
- DOI: 10.1038/nrneurol.2013.275
Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases
Abstract
Misfolding and intracellular aggregation of α-synuclein are thought to be crucial factors in the pathogenesis of Lewy body diseases (LBDs), such as Parkinson disease. However, the pathogenic modifications of this protein and the mechanisms underlying its activity have not been fully characterized. Recent studies suggest that small amounts of α-synuclein are released from neuronal cells by unconventional exocytosis, and that this extracellular α-synuclein contributes to the major pathological features of LBD, such as neurodegeneration, progressive spreading of α-synuclein pathology, and neuroinflammation. In this article, we review a rapidly growing body of literature on possible mechanisms by which extracellular α-synuclein contributes to LBD pathology, and discuss therapeutic approaches to target this form of α-synuclein to halt disease progression.
Similar articles
-
Pathological roles of α-synuclein in neurological disorders.Lancet Neurol. 2011 Nov;10(11):1015-25. doi: 10.1016/S1474-4422(11)70213-7. Lancet Neurol. 2011. PMID: 22014436 Review.
-
Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.J Mol Neurosci. 2008;34(1):17-22. doi: 10.1007/s12031-007-0012-9. Epub 2007 Apr 17. J Mol Neurosci. 2008. PMID: 18157654 Review.
-
Complicity of α-synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in Lewy body disease.Arch Pharm Res. 2021 Jun;44(6):564-573. doi: 10.1007/s12272-021-01334-6. Epub 2021 Jun 10. Arch Pharm Res. 2021. PMID: 34114191 Free PMC article. Review.
-
14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.J Neurosci. 2018 Sep 19;38(38):8211-8232. doi: 10.1523/JNEUROSCI.1134-18.2018. Epub 2018 Aug 9. J Neurosci. 2018. PMID: 30093536 Free PMC article.
-
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.Exp Neurol. 2013 Feb;240:190-204. doi: 10.1016/j.expneurol.2012.11.020. Epub 2012 Nov 28. Exp Neurol. 2013. PMID: 23201181 Free PMC article.
Cited by
-
Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.J Neurosci. 2016 May 4;36(18):5144-59. doi: 10.1523/JNEUROSCI.4658-15.2016. J Neurosci. 2016. PMID: 27147665 Free PMC article.
-
The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson's Disease Mouse Models.J Neuroimmune Pharmacol. 2021 Jun;16(2):470-482. doi: 10.1007/s11481-020-09943-6. Epub 2020 Jul 15. J Neuroimmune Pharmacol. 2021. PMID: 32671618
-
Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.Int J Mol Sci. 2021 Nov 18;22(22):12467. doi: 10.3390/ijms222212467. Int J Mol Sci. 2021. PMID: 34830348 Free PMC article. Review.
-
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid.Sci Transl Med. 2020 Feb 5;12(529):eaay1809. doi: 10.1126/scitranslmed.aay1809. Sci Transl Med. 2020. PMID: 32024798 Free PMC article.
-
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.Neurobiol Dis. 2016 Jul;91:59-68. doi: 10.1016/j.nbd.2016.02.018. Epub 2016 Feb 24. Neurobiol Dis. 2016. PMID: 26921471 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical